非外伤非糖尿病视网膜病变性玻璃体积血病因分析及手术疗效

目的 分析非外伤性非糖尿病视网膜病变性玻璃体积血的病因及手术疗效.方法 2006年3月至2009年7月期间住院手术的174例(176只眼)出现大量玻璃体积血的非糖尿病视网膜病变、非眼外伤患者的出血原因及手术情况进行了回顾性分析.结果 视网膜静脉阻塞(retinal vein occlusion,RVO)73只眼;视网膜静脉周围炎25只眼;视网膜裂孔或脱离(retinal hole/retinal detachment,(RH/RD)25只眼;渗出型年龄相关性黄斑变性(exudative age-related macular degeneration,EAMD)22只眼;息肉状脉络膜血管病变(polypoidal choroidal vasculopathy,PCV)15只眼;共占90.9%,为非外伤性非糖尿病视网膜病变性玻璃体积血的主要原因.术后视力提高者达90%以上.结论 RVO,Eales病,视网膜裂孔,EAMD,PCV是非外伤非糖尿病视网膜病变性玻璃体积血的主要病因,玻璃体切割手术是治疗玻璃体积血的有效方法.

Abstract：

Objective To analyze the etiological factors in non-traumatic non-diabetec retinopathic vitreous hemorrhage and to investigate the clinical outcomes of vitrectomy in such patients.Methods The etiologic factor and recovery rate of visual functions in a total of 174 patients (176 eyes) undergoing vitrectomy with follow-up records from March 2006 to July 2009 in our department were analyzed retrospectively.Results Vitreous hemorrhage was found in 73 eyes of retinal vein occlusion (RVO),25 eyes of Eales' disease,25 eyes of retinal hole or retinal detachment (RH/RD),22 eyes ofexudative age-related macular degeneration (EAMD),and 15 eyes ofpolypoidal choroidal vasculopathy (PCV),amounting to 90.9% of total eyes.The visual improvement rate after vitrectomy was more than 90%.Conclusions RVO,Eales' disease,RH/RD,EAMD and PCV are main causes of non-traumatic non-diabetec retinopathic vitreous hemorrhage.Vitrectomy is an effective way for vitreous hemorrhage.     

玻璃体积血的病因分析及手术治疗的疗效

目的：探讨玻璃体积血的病因及行玻璃体切割术治疗的临床疗效。

方法：对162例173眼玻璃体积血患者进行病因分析,采用玻璃体切割术治疗。

结果：术后诊断：173眼中增殖期糖尿病视网膜病变83眼(48.0%),视网膜分支静脉阻塞24眼(13.9%),Eales病13眼(7.5%),视网膜中央静脉阻塞10眼(5.8%),外伤性玻璃体积血9眼(5.2%),视网膜裂孔8眼(4.6%),视网膜脱离9眼(5.2%),增生性玻璃体视网膜病变7眼(4.0%),单纯玻璃体积血4眼(2.3%),视网膜大动脉瘤2眼(1.2%),息肉样脉络膜血管病变2眼(1.2%),脉络膜视网膜炎1眼(0.6%),年龄相关性黄斑病变1眼(0.6%)。不同年龄病因分布不同,术后随访3～15mo,术前与术后视力相比,41眼(23.7%)视力不变,115眼(66.5%)视力提高,17眼(9.8%)视力下降。术后视力与术前相比差异具有统计学意义( P<0.05)。

结论：增殖期糖尿病视网膜病变、视网膜分支静脉阻塞、Eales 病是导致玻璃体积血的主要原因。玻璃体切割联合术手术并发症少,能在一定程度上提高患者视力,是治疗玻璃体积血安全有效的方法。     

Photocoagulation in Eales' disease

Between 1970 and 1991 the authors examined 466 cases with Eales' disease. 359 eyes of 295 of these 466 cases received photocoagulation treatment. The mean age was 30.4, ranging between 14 and 55 years. Ten eyes with persistent vitreous hemorrhage underwent pars plana vitrectomy before photocoagulation. 210 eyes were treated with xenon arc, 135 with argon laser, 12 with krypton laser and two with yellow dye laser. Hypoxic areas and retinal neovascularizations were closed completely in 298 eyes. In 21 eyes with elevated neovascularizations intruding into the vitreous cavity feeder vessel photocoagulation was used. 24 eyes with disc neovascularization were treated with panretinal photocoagulation. 12 eyes with branch vein occlusion and four eyes with central vein occlusion received photocoagulation treatment to areas of non-perfusion and retinal neovascularization. At a mean follow-up of 43 months, seven new retinal neovascularizations and three new disc neovascularizations developed in eyes which previously had received photocoagulation for retinal neovascularization and hypoxia. Nine out of 21 eyes with elevated neovascularizations developed vitreous hemorrhage. Disc neovascularization resolved completely in 13 out of 24 eyes, it partially regressed in eight eyes and did not respond to treatment in three eyes. The visual acuities were improved in 12.3%, maintained in 77.4% and deteriorated in 10.3% of the eyes after treatment. Periodic follow-up and early photocoagulation treatment is useful in stabilizing the retinal lesions and in maintaining functional levels of vision in Eales' disease.     

Vitrectomy for nondiabetic vitreous hemorrhage

In a group of 94 eyes with nondiabetic vitreous hemorrhage that underwent pars plana vitrectomy between March 1974 and September 1982, the causes of the hemorrhages were retinal branch vein obstruction (36 eyes), blunt trauma (11 eyes), cataract extraction (ten eyes), subretinal neovascularization (nine eyes), Eales' disease (eight eyes), Terson's syndrome (four eyes), and idiopathic (five eyes) and miscellaneous (11 eyes) conditions. Vision was improved postoperatively in 88 of the 94 eyes, including all of those that underwent blunt trauma or cataract extraction, those with Eales' disease and Terson's syndrome, and those in the idiopathic and miscellaneous groups. Final visual acuities, which depended primarily on the underlying condition and its effect on the macula, were 20/20 or better in ten eyes, 20/25 to 20/40 in 37 eyes, 20/50 to 20/200 in 26 eyes, 20/300 to 20/400 in 11 eyes, 9/200 to 5/200 in three eyes, and hand movements or light perception in seven eyes. Retinal tears, the most common surgical complication, occurred in 18 eyes. The incidence of anterior retinal tears was reduced from 11% (11 of 38 eyes) to 4% (two of 56 eyes) after we began using a vitrectomy probe with a smaller diameter. Some postoperative lens opacification occurred in 16 of 50 phakic eyes, and the incidence of later lens opacification increased as the follow-up lengthened.     

玻璃体切除治疗视网膜分支静脉阻塞引起玻璃体积血的临床效果

目的:探讨玻璃体切除手术治疗视网膜分支静脉阻塞引起的玻璃体积血的临床效果。方法:回顾分析28例28眼视网膜分支静脉阻塞引起的玻璃体积血患者进行闭合式玻璃体切除,联合增殖膜剥离、眼内激光光凝及玻璃体腔长效气体、硅油或灌注液填充手术的临床疗效。结果:该28例患者术中均可见视网膜分支静脉阻塞闭锁呈白线状。视网膜静脉阻塞颞上方20例,颞下方8例。合并视盘新生血管2例,18例阻塞区可见视网膜新生血管及交通支。并发视网膜脱离7例,患者术前及术后视力比较有统计学差异(P<0.05)。结论:玻璃体切除是视网膜分支阻塞的有效手术方法,术中应谨慎去除阻塞区增殖病灶,光凝视网膜无灌注区,术后注意观察阻塞部位的视网膜复位及增殖情况。     

Vitrectomy for pars planitis complicated by vitreous hemorrhage: visual outcome and long-term follow-up

PURPOSE: To characterize the visual results of vitrectomy for nonclearing vitreous hemorrhage in pars planitis. METHODS: Case series. RESULTS: All six eyes (100%) had a visual acuity of 20/200 or less preoperatively. Postoperatively, five eyes (83%) improved to a final visual acuity of better than 20/30, and one eye improved to 20/100. The poorer vision of the latter patient was attributed to cystoid macular edema. Postoperative follow-up range was from 1.3 to 9 years (mean, 4.2 years). CONCLUSION: A substantial long-term benefit is seen in patients with pars planitis treated with vitrectomy for nonclearing vitreous hemorrhage. A larger case series will be needed to confirm whether such excellent outcomes can be expected.     

Pars plana vitrectomy for vitreous hemorrhage and retinal vein occlusion

We studied 16 cases of retinal vein occlusion and vitreous hemorrhage treated by pars plana vitrectomy. The visual acuity in all nine eyes suffering from branch vein occlusion was improved postoperatively, reaching an acuity of 6/6 to 6/12 in 33% of the patients. In the seven eyes suffering from central vein occlusion, however, the postoperative visual acuity results were poor. The incidence of postoperative complications was higher also in the central vein occlusion group.     

视网膜静脉阻塞性玻璃体积血的玻璃体切割手术疗效观察

目的观察玻璃体切割手术治疗视网膜静脉阻塞（RVO）性玻璃体积血的疗效。方法回顾性整理分析2006年3月至2009年6月在我院行玻璃体切割手术的玻璃体积血患者241例,其中RVO者28例（28只眼）（占11.6%）。随访6个月至2年观察患者的发病特点、视力预后、RVO相关并发症及手术相关并发症的发生情况。结果 26例患者术后视力较术前不同程度提高,占92.9%,2例术后视力保持不变,占7.1%。中央静脉阻塞11例,分支静脉阻塞17例。分支静脉阻塞术后视力好于中央静脉阻塞（P〈0.0235）。玻璃体积血时间小于2个月的患者（10例）视力预后好于2个月后手术者（18例）（P〈0.05）。玻璃体切除联合白内障超声乳化手术者较单纯玻璃体切除术者视力提高有统计学差异（P〈0.05）。结论玻璃体切割手术是治疗RVO性玻璃体积血的有效方法。手术时机一般选在经药物治疗2～3个月积血仍不吸收时进行。白内障摘除联合玻璃体切割手术治疗合并白内障的RVO性玻璃体积血是安全有效的。     

Vitrectomy for nondiabetic vitreous hemorrhage. Not associated with vascular disease

Forty-nine consecutive eyes with nonclearing vitreous hemorrhage not associated with retinal or choroidal vascular disease underwent vitrectomy. Etiologies included vitreous hemorrhage during anterior segment surgery (22 eyes), blunt trauma (8 eyes), retinal tears with and without retinal detachment (8 eyes), Terson's syndrome (2 eyes), avulsed retinal vessel (1 eye), and idiopathic cases (8 eyes). The final visual acuity improved in 48 eyes (98%). Follow-up was 6-91 months (mean, 20 months). Of the 49 eyes, 40 eyes (82%) had a best postoperative visual acuity of 20/100 or better, 31 eyes (63%) had visual acuity of 20/40 or better, and 12 eyes (24%) had visual acuity of 20/20. The major complications included intraoperative iatrogenic retinal breaks (5 eyes), postoperative progressive cataract (7 eyes), late retinal detachment (4 eyes) and recurrent vitreous hemorrhage (2 eyes). The major complication associated with later visual loss was progressive cataract.     

Therapeutic effects of laser photocoagulation and/or vitrectomy in Eales' disease

PURPOSE: To determine visual outcomes and regression of retinal neovascularization following laser photocoagulation and/or vitrectomy in eyes with Eales' disease. METHODS: In a retrospective noncomparative study, the authors reviewed the existing data of 67 eyes of 54 patients with a diagnosis of Eales' disease who had undergone laser photocoagulation and/or vitrectomy based on their clinical presentations. Main outcome measures were visual acuity changes and regression of retinal neovascularization of the eyes following treatment. RESULTS: Both laser therapy and vitrectomy improved visual acuity and induced regression of retinal neovascularization. Forty-three eyes had undergone laser therapy; their rate of visual acuity 320/30 improved from 53% before treatment to 60% after treatment. Twenty-four eyes had undergone vitrectomy; rate of visual acuity 320/30 improved from 13% before surgery to 38% after surgery. In eyes that had undergone laser therapy, additional laser therapy controlled recurrent neovascularization in 47% of the eyes, but ultimately, 12% of them required vitrectomy. In the primary vitrectomized group, additional required treatment was repeat vitrectomy in 21%, and/or laser therapy in 29% of the eyes. CONCLUSIONS: Although laser photocoagulation should be the first line of treatment in Eales' disease, it cannot always induce regression of retinal neovascularization. In such cases vitrectomy may further enhance therapeutic success.     

动静脉鞘膜切开治疗视网膜分支静脉阻塞

目的观察动静脉鞘膜切开术治疗视网膜分支静脉阻塞的临床效果.方法对3例(3只眼)视力低于0.1的视网膜分支静脉阻塞患者进行平坦部玻璃体切割术和动静脉鞘膜切开术.结果 3只眼术后玻璃体清亮,视力均有不同程度的提高,视网膜内出血和黄斑水肿明显减轻,无手术并发症发生.结论动静脉鞘膜切开术是治疗视力较差的视网膜分支静脉阻塞的有效方法.     

Outcomes of vitreoretinal surgery for complications of branch retinal vein occlusion

OBJECTIVE: To investigate outcomes of vitreoretinal surgery for complications of branch retinal vein occlusion (BRVO). DESIGN: Retrospective, noncomparative case series. PARTICIPANTS: The medical records of all patients who underwent vitreoretinal surgery for complications of BRVO at Bascom Palmer Eye Institute between January 1, 1991 and December 31, 1998 were reviewed. Thirty-six eyes from 36 consecutive patients were identified. MAIN OUTCOME MEASURES: Visual acuity outcomes include preservation of preoperative visual acuity and visual acuity greater than or equal to 20/40, 20/200 and 5/200. When preoperative retinal detachment was present, the anatomic outcome assessed was complete retinal attachment. Postoperative event rates of retinal detachment, vitreous hemorrhage, epiretinal membrane (ERM), and cataract were tabulated. All outcomes were assessed at 6 months. RESULTS: Surgical indications included nonclearing vitreous hemorrhage (17 patients), traction retinal detachment involving the macula (15), and ERM (4). Mean follow-up was 19 months. Preoperatively, best-corrected vision was greater than or equal to 20/200 in 19/36 (53%) eyes. Six months postoperatively, best-corrected vision was greater than or equal to 20/40 in 12/36 (33%) eyes, greater than or equal to 20/200 in 27/36 (75%) eyes, and greater than or equal to 5/200 in 31/36 (86%) eyes. Postoperative complications included retinal detachment (2/36; 6% eyes), ERM (3; 8%), vitreous hemorrhage (2; 6%), suprachoroidal hemorrhage (1; 3%), central retinal vein occlusion (1; 3%), and central retinal artery occlusion (1; 3%). Clinical features associated with better visual outcome include better preoperative visual acuity (P: = 0.05), absence of preoperative afferent pupillary defect (P: = 0.01), and absence of preoperative macular edema (P: = 0.08). CONCLUSIONS: Following surgery, retinal attachment and improved visual acuity were achieved in the majority of patients. Pre-existing pathology and postoperative complications may limit final vision in eyes with BRVO.     

视网膜中央静脉阻塞玻璃体积血合并原发性高血压的手术疗效

目的:分析视网膜中央静脉阻塞玻璃体积血合并原发性高血压的手术疗效.方法:回顾性分析2011-03/2015-03因玻璃体积血在我院行玻璃体切割的原发性高血压患者83例83眼,根据术中所见,其中有28眼玻璃体积血由视网膜中央静脉阻塞引起,术后随访9~36(平均22.4)mo.检查记录患者手术前后最佳矫正视力、术后并发症情况,并进行统计分析.结果:视网膜中央静脉阻塞玻璃体积血合并原发性高血压发生率为33.7%;术后最佳矫正视力3.3~4.5,术后最佳矫正视力提高24眼(86%),视力不变4眼(14%),无视力下降患者,手术前后视力相比差异有统计学意义(P<0.05);术后发生黄斑水肿5眼,发生率18%;所有患者术后均没有发生视网膜脱离及复发玻璃体积血.结论:手术治疗合并原发性高血压的视网膜中央静脉阻塞玻璃体积血疗效好,可减少并发症,提高视力.     

有晶状体眼的全玻璃体切除术

目的 :探讨有晶状体眼切除全玻璃体的可能性及其效果。方法 :对 4 8例 ( 50只 )有晶状体眼患者 ,做标准经睫状体平部三通道玻璃体切除术 ,同时将基底部和睫状体平部玻璃体一起切除。其中裂孔性视网膜脱离 1 4只眼 (包括巨大裂孔 3只眼 ) ,闭合性眼外伤 4只眼和开放性眼外伤 1 1只眼 (包括化脓性眼内炎 2只眼 ) ,黄斑部疾病 7只眼 ,各种原因玻璃体出血 5只眼 ,静脉周围炎 4只眼 ,急性视网膜坏死综合征 3只眼 ,糖尿病性视网膜病变 2只眼。手术后定期检查视力、眼球前段、眼底和眼压 ,最后复诊时用压陷三面镜检查并在再次手术中探查睫状体平部。结果 :充分全玻璃体切除 38只眼 ,部分全玻璃体切除 1 2只眼。无巩膜穿刺孔玻璃体嵌顿和轻度嵌顿者占 86 % ,未发生前段增生性玻璃体视网膜病变。无咬伤晶状体和睫状体并发症。一次手术成功率是 90 % ,再次视网膜和玻璃体手术总的成功率是 94 % ,患者视力较术前明显提高 (P <0 .0 5)。主要并发症是医源性视网膜裂孔、角膜上皮水肿、巩膜穿刺孔并发症、青光眼、视网膜再脱离和术中术后白内障。结论 :有晶状体眼全玻璃体切除术切实可行 ,能预防或减少与巩膜穿刺孔相关的并发症和前段增生性玻璃体视网膜病变。     

Combined surgery, phacoemulsification, implantation of intraocular lens and pars plana vitrectomy

PURPOSE: To evaluate the effectiveness, technical feasibility and incidence of complications after combining pars plana vitrectomy, phacoemulsification and intraocular lens implantation. MATERIAL AND METHODS: The results of combined vitreoretinal and cataract surgery in 100 eyes of 96 patients were retrospectively and prospectively analyzed. The mean follow-up period was 8.4 months. All patients had clinically significant lens opacities and vitreoretinal pathology requiring pars plana vitrectomy. Indications for vitreoretinal surgery included: persistent vitreous haemorrhage (28 eyes), vitreous hemorrhage combined with tractional retinal detachment (50 eyes), tractional retinal detachment without vitreous haemorrhage caused by proliferative diabetic retinopathy (7 eyes), rheumatogenous retinal detachment with proliferative vitreoretinopathy (10 eyes) and dislocated crystalline lens in the vitreous (5 eyes). RESULTS: Postoperatively, best corrected visual acuity improved in 81 eyes (81%)- by two lines or more in 31 eyes (31%) - by less than two lines in 50 eyes (50%). In 14 eyes (14%) visual acuity was unchanged and was worse in 5 cases (5%). Postoperative complications included fibrin reaction, posterior synechias of the iris, vitreous hemorrhage, neovascular glaucoma, posterior capsule opacification, redetachment of retina. CONCLUSIONS: Our cases confirm previous study, that performing phacoemulsification, IOL implantation and vitrectomy in one operation is safe and allows visual recovery with good technical results.     

玻璃体腔注射Avastin治疗眼底病400例临床疗效总结

目的:通过对400例眼底病患者520眼经玻璃体腔注射avastin治疗的临床疗效观察,说明玻璃体腔注射avastin对视网膜静脉阻塞(RVO)、糖尿病性视网膜病变(DR)、年龄相关性黄斑变性(ARMD)、中心性浆液性脉络膜视网膜病变(CSC)、视网膜脉络膜新生血管(CNV)等眼底病的治疗能起到重要的作用,并对其副作用作了总结分析统计。方法:对我院门诊确诊为RVO,DR,ARMD,CSC,CNV等眼底病患者400例眼底病患者520眼进行玻璃体腔注射avastin治疗,注射治疗1次/mo,以治疗前后的视力、眼底荧光血管造影(FFA)、眼压、光学相干断层扫描(OCT)作为观察指标,对经玻璃体腔注射avastin治疗的疗效进行分析总结;并对治疗过程当中出现的并发症作了总结、分析。结果:随访时间为3mo～1a,520眼中有467眼(89.8%)视力提高2行以上,眼压正常、视网膜水肿及出血明显吸收,新生血管消退,OCT及FFA指标都有好转;36眼(6.9%)视力稳定,治疗前后视力无变化,但眼底情况都有改善,无新生血管增生加重或眼压升高等并发症的发生;17眼(3.3%)视力下降,其中有13眼(2.5%)从0.2降至0.1,病变稳定;1眼(0.2%)发生了眼内炎,视力从0.6下降至0.2;1眼(0.2%)发生了视网膜中央动脉阻塞(CRAO),视力从0.02变为光感;1眼(0.2%)发生了玻璃体出血;1眼(0.2%)发生了孔源性视网膜脱离,伴有并发症而视力下降的患者中除了1眼(CRAO)外其余在对症治疗后视力均有提高;在所有的治疗眼中发生一过性眼压升高20眼(3.8%),后经降眼压对症治疗后眼压正常。还有1例患者右眼行玻璃体腔注射avastin治疗后3d左眼施行了小梁切除手术,术后切口愈合较一般手术后慢7～10d,眼压相对较低。结论:经玻璃体腔注射avastin治疗视RVO,DR,ARMD,CSC,CNV等眼底病,是一种有效、安全的方法,能提高视力,减轻黄斑和视网膜水肿,促进玻璃体和视网膜下出血的吸收,能有效地消退视网膜和脉络膜新生血管,可以抑制虹膜红变和新生血管性青光眼的发生;对于在治疗过程中出现的并发症也是值得我们去总结、思考的。     

Pars plana vitrectomy for regression of choroidal neovascularization with age-related macular degeneration

OBJECTIVE: In age-related macular degeneration, the posterior vitreous surface often remains attached to a higher degree than expected for the patient's age, suggesting the involvement of the posterior vitreous membrane in the pathophysiology of choroidal neovascularization. Thus, we performed simple pars plana vitrectomy and artificial posterior vitreous detachment in order to induce regression of choroidal neovascularization. METHODS: Vitrectomy was performed in 12 eyes of 11 patients with age-related macular degeneration in whom the posterior vitreous surface remained attached, and in whom there was evidence of highly active choroidal neovascularization. The posterior vitreous membrane was artificially detached during surgery, but photocoagulation and/or a subretinal procedure for choroidal neovascularization was not performed. Patients underwent fluorescein and indocyanine green angiography both pre- and postoperatively to assess the status of choroidal neovascularization. RESULTS: Six months after surgery, 6 of the 12 eyes showed regression of choroidal neovascularization, and in 2 eyes it had disappeared completely. Subretinal exudative changes in 8 eyes had improved. Visual acuity testing showed improved vision in 4 eyes, unchanged vision in 4 eyes, and worsening of vision in 4 eyes. The final best corrected visual acuity was 10/20 or better in one eye, 10/ 20 to 20/200 in 7 eyes, and 20/200 or worse in 4 eyes. CONCLUSION: The results of the present study suggest the involvement of the posterior vitreous membrane in the pathophysiology of age-related macular degeneration. Furthermore, the minimally invasive pars plana vitrectomy may represent a new treatment for age-related macular degeneration.     

Submacular surgery to remove choroidal neovascularization associated with central serous chorioretinopathy

PURPOSE: To report the results of submacular surgery for removal of choroidal neovascularization associated with central serous chorioretinopathy. METHODS: Ten eyes of nine consecutive patients with central serous chorioretinopathy and subfoveal or juxtafoveal choroidal neovascularization underwent pars plana vitrectomy with removal of the choroidal neovascular membrane between January 1994 and January 1999.RESULTS: All 10 eyes (nine patients) were followed postoperatively for at least 6 months. The mean postoperative follow-up was 23 months (range, 6 to 56.5 months). The patients were followed for an average of 6.2 months from the time of symptoms to the removal of the choroidal neovascularization. Preoperative mean best-corrected visual acuity was 20/100 (range, 20/25 to 20/400), and postoperative best-corrected mean visual acuity was 20/60 + 2 (range, 20/20 to 20/400). Seven eyes had improved postoperative visual acuity, with an average of 3.4 lines gained. Of the three eyes that had worse acuity, an average of 1.3 lines of visual acuity was lost; final mean postoperative visual acuity was 20/80 + 1 (range, 20/25 to 20/400). Of the six eyes with symptoms of less than 3 months' duration, four had a final visual acuity of 20/50 or better. All three eyes with 20/300 or worse final visual acuity had loss of foveal retinal pigment epithelium after surgery; the remaining eyes had preserved retinal pigment epithelium with a visual acuity of 20/70 or better. Two eyes had intraoperative peripheral retinal tears, and two eyes had recurrence of the choroidal neovascular complex. CONCLUSIONS: The anatomic and visual results in eyes with choroidal neovascularization associated with central serous chorioretinopathy are modestly encouraging and suggest that submacular surgery for choroidal neovascularization in patients with central serous chorioretinopathy is a treatment option that may salvage good macular function in some eyes.     

玻璃体切除治疗复发性出血性玻璃体视网膜疾病

目的探讨玻璃体切除术对复发性出血性玻璃体视网膜疾病的临床效果。方法对43例(44眼)玻璃体积血施行三通道经睫状体平坦部玻璃体切除术,联合膜剥离,水下透热,眼内光凝(或经巩膜冷凝),并根据病情选用眼内长效填充材料。结果视网膜静脉阻塞18眼,外伤性玻璃体积血9眼,视网膜裂孔致玻璃体积血6眼,静脉周围炎5眼,增生性糖尿病视网膜病变3眼,蛛网膜下腔出血合并玻璃体积血(综合症)2眼,老年性黄斑变性1眼。术后随访2～24月,44眼视力均有不同程度的提高,随访视力较术前相比差异有统计学意义(P<0.05),视力0.05以上者36眼(81.82%),0.2～0.8者27眼(61.36%)。结论复发性出血性玻璃体视网膜疾病经药物治疗无效,B超显示出现玻璃体后脱离或B超显示伴有牵引性视网膜脱离者,玻璃体切除术是消除玻璃体积血并使视网膜复位的有效方法。